Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmonary sarcoidosis.

Joseph P Lynch1, Yan Ling Ma, Michael N Koss

  • 1Division of Pulmonary, Critical Care Medicine, and Hospitalists, Department of Internal Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA. jplynch@mednet.ucla.edu

Seminars in Respiratory and Critical Care Medicine
|March 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durotaxis is a driver and potential therapeutic target in lung fibrosis and metastatic pancreatic cancer.

Nature cell biology·2025
Same author

Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis.

ERJ open research·2024
Same author

Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial.

ERJ open research·2024
Same author

Assessing How Patients Feel, Function, and Survive in Idiopathic Pulmonary Fibrosis: The Best Is the Enemy of the Good.

American journal of respiratory and critical care medicine·2024
Same author

The American Thoracic Society Research Program: Twenty Years of Driving Discovery in Respiratory Medicine.

American journal of respiratory and critical care medicine·2024
Same author

Three dimensional fibrotic extracellular matrix directs microenvironment fiber remodeling by fibroblasts.

Acta biomaterialia·2024

Sarcoidosis is a multi-organ granulomatous disease where lung involvement is common, affecting 85-95% of patients. While many cases resolve spontaneously, some progress to chronic lung disease, requiring treatment like corticosteroids or lung transplantation.

Area of Science:

  • Pulmonology
  • Immunology
  • Internal Medicine

Background:

  • Sarcoidosis is a multisystem granulomatous disease of unknown cause.
  • Pulmonary manifestations are the most common presentation, seen in 85-95% of patients.
  • Many patients are asymptomatic, with incidental radiographic findings.

Purpose of the Study:

  • To summarize the clinical presentation, course, and management of pulmonary sarcoidosis.
  • To highlight the variability in disease expression and outcomes.
  • To discuss treatment options for severe or refractory cases.

Main Methods:

  • Review of existing literature on pulmonary sarcoidosis.
  • Analysis of clinical findings, diagnostic criteria, and treatment outcomes.
  • Synthesis of information on disease progression and prognosis.

Related Experiment Videos

Main Results:

  • Pulmonary function abnormalities are frequent, correlating with symptoms like cough and dyspnea.
  • Spontaneous remission occurs in approximately two-thirds of patients.
  • Chronic disease affects up to 30%, potentially leading to progressive, life-threatening lung function loss.

Conclusions:

  • Pulmonary sarcoidosis exhibits diverse clinical courses, ranging from spontaneous resolution to chronic, progressive lung disease.
  • Corticosteroids are a primary treatment, with other immunosuppressive agents or lung transplantation reserved for severe cases.
  • Effective management requires individualized approaches based on disease severity and patient response.